Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC.
|
31821109 |
2020 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
|
31669267 |
2020 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The American Society of Clinical Oncology/College of American Pathologists recently updated their recommendations on human epidermal growth factor receptor 2 (HER2) testing by fluorescence in situ hybridization (FISH) in invasive breast cancer, with a focus on the clarification of less common test patterns of ISH.
|
31375912 |
2020 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast cancer patients and those after NAC among patients who did not achieve pathological complete response (pCR) using conventional adjuvant trastuzumab.
|
31574500 |
2020 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 status in different blocks from the same tumor in primary invasive breast cancer was highly concordant.
|
31388934 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed data from BCCs for a selected indicator: the recommendation of trastuzumab for patients with early HER-2-positive invasive breast cancer.
|
31062148 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patient management of invasive breast cancer (IBC) is to a large extent based on hormone- and HER2-receptor assessment.
|
30825048 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
|
31849525 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is conflicting data in the literature that describes the expression of these receptors in breast cancer, and the aim of this study is to test the expression of CD30 and ALK in a cohort of Middle Eastern patients with breast carcinoma.Cases of invasive breast cancer from the archives of AUBMC were reviewed over a period of 9 years, and the blocks that were used for immunohistochemical staining for ER, PR, Her-2/neu were selected.
|
31393373 |
2019 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histopathological examination and analysis of estrogen (ER), progesterone (PR) and HER2 receptors expression in MpBC patients and their comparison to other types of invasive breast cancer has been performed.
|
30553188 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estimating over-amplification of human epidermal growth factor receptor 2 (HER2) on invasive breast cancer is regarded as a significant predictive and prognostic marker.
|
30908205 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reviewed the medical records of 296 premenopausal patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary invasive breast cancer treated between 2008 and 2015.
|
31252399 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 IHC scores and HER2 copy numbers can provide prognostic information for patients with HER2-positive invasive breast cancer.
|
30515868 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective, exploratory study included patients (≥ 18 years old) treated at our center (2005-2009) who had ER+ , HER2-negative invasive breast cancer and synchronous nodal metastases with available tumor blocks from both sites.
|
31302854 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study was performed to investigate the diagnostic value of an alternative CEP17 reference probe for HER2 status in invasive breast cancer.
|
31410164 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with newly diagnosed, node negative, hormone receptor positive, and HER2 negative invasive breast cancer were randomized to undergo a Magee calculation or not.
|
30672056 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer.
|
30787125 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone.
|
30516102 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We retrospectively reviewed the HER2 FISH testing results from 2233 cases of invasive breast cancer between January 2014 and December 2017.
|
30712197 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have reported up to 50% of ductal carcinoma in situ (DCIS), is HER2 positive, but the frequency of HER2-positive invasive breast cancer (IBC) is lower.
|
31065110 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a retrospective review of ER<sup>+</sup>/HER2- invasive breast cancer (BC) with ODXRS results from 2 institutions (n = 816) between 2006 and 2018.
|
30509870 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Patients and methods:</b> Three hundred sixty-seven female patients with HER-2-positive invasive breast cancer who were treated with one-year adjuvant trastuzumab were analysed in this retrospective study.
|
31114373 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
So it can be added to the hormonal receptors and HER 2 assay in the routine management of invasive breast cancer after confirmation on a more larger study.
|
30738694 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer.
|
30420102 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [<sup>18</sup>F]FDG PET/CT.
|
30652258 |
2019 |